Claims:

1. Use of a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide in the manufacture of a medicament for the treatment of multiple sclerosis.

2. Use of a pharmaceutical combination according to claim 1, wherein the first active ingredient is ponesimod and the second active ingredient is teriflunomide.

3. Use of a pharmaceutical combination according to claim 1, wherein the first active ingredient is ponesimod and the second active ingredient is leflunomide.

4. Use of a pharmaceutical combination according to any one of claims 1 to 3, wherein the first and the second active ingredient are comprised in a single pharmaceutical composition.

5. Use of a pharmaceutical combination according to any one of claims 1 to 3, wherein the first and the second active ingredient are comprised in separated pharmaceutical compositions.

6. Use of a pharmaceutical composition containing ponesimod and at least one therapeutically inert excipient in the manufacture of a medicament, for the prevention or treatment of multiple sclerosis, wherein said medicament is to be administered in combination with a second medicament containing teriflunomide or leflunomide and at least one therapeutically inert excipient.

7. Use of a pharmaceutical composition containing teriflunomide or leflunomide and at least one therapeutically inert excipient, in the manufacture of a medicament for the prevention or treatment of multiple sclerosis, wherein said medicament is to be administered in combination with a second medicament containing ponesimod and at least one therapeutically inert excipient.